KRYS Insider Trading

Insider Ownership Percentage: 13.70%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $21,316,265.00

Krystal Biotech Insider Trading History Chart

This chart shows the insider buying and selling history at Krystal Biotech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$20M-$10M$0$10M$20MTotal Insider BuyingTotal Insider Selling

Krystal Biotech Share Price & Price History

Current Price: $170.57
Price Change: Price Increase of +0.84 (0.49%)
As of 04/29/2025 05:00 PM ET

This chart shows the closing price history over time for KRYS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarApr$169.73Closing price on 04/28/25:

SEC Filings (Institutional Ownership Changes) for Krystal Biotech (NASDAQ:KRYS)

86.29% of Krystal Biotech stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at KRYS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$28Mbought$8.71MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$200M-$100M$0$100M$200MTotal InflowsTotal Outflows
Krystal Biotech logo
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Read More on Krystal Biotech

Today's Range

Now: $170.57
Low: $163.77
High: $171.74

50 Day Range

MA: $176.24
Low: $158.69
High: $194.44

52 Week Range

Now: $170.57
Low: $141.72
High: $219.34

Volume

257,536 shs

Average Volume

295,447 shs

Market Capitalization

$4.93 billion

P/E Ratio

57.05

Dividend Yield

N/A

Beta

0.75

Who are the company insiders with the largest holdings of Krystal Biotech?

Krystal Biotech's top insider investors include:
  1. Suma Krishnan (Insider)
  2. Daniel Janney (Director)
  3. Kathryn Romano (CAO)
  4. Andrew C Orth (Insider)
  5. Julian S Gangolli (Director)
Learn More about top insider investors at Krystal Biotech.

Who are the major institutional investors of Krystal Biotech?

Krystal Biotech's top institutional shareholders include:
  1. Bank of New York Mellon Corp — 0.59%
  2. Principal Financial Group Inc. — 0.44%
  3. GAMMA Investing LLC — 0.42%
  4. Handelsbanken Fonder AB — 0.26%
  5. Rhumbline Advisers — 0.24%
  6. Janney Montgomery Scott LLC — 0.16%
Learn More about top institutional investors of Krystal Biotech stock.

Which major investors are selling Krystal Biotech stock?

Within the previous quarter, KRYS stock was sold by these institutional investors:
  1. Allspring Global Investments Holdings LLC
  2. Handelsbanken Fonder AB
  3. Janney Montgomery Scott LLC
  4. Hennion & Walsh Asset Management Inc.
  5. Parallel Advisors LLC
  6. Illinois Municipal Retirement Fund
  7. Teacher Retirement System of Texas
  8. Rhumbline Advisers
During the previous year, company insiders that have sold Krystal Biotech company stock include:
  1. Suma Krishnan (Insider)
  2. Daniel Janney (Director)
  3. Kathryn Romano (CAO)
Learn More investors selling Krystal Biotech stock.

Which major investors are buying Krystal Biotech stock?

During the last quarter, KRYS stock was purchased by institutional investors including:
  1. GAMMA Investing LLC
  2. Lisanti Capital Growth LLC
  3. Roman Butler Fullerton & Co.
  4. Principal Financial Group Inc.
  5. Wealthquest Corp
  6. Oppenheimer Asset Management Inc.
  7. Summit Global Investments
  8. Elevation Point Wealth Partners LLC